ClinicalTrials.gg
CompletedNCT05661591Updated Apr 4, 2023

Effect of Fluconazole on Pharmacokinetics of SHR2554 in Healthy Subjects

A Phase 1 interventional study of SHR2554 Tablets and Fluconazole Capsules in Malignant Tumor, sponsored by Jiangsu HengRui Medicine Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-04-04.

Sponsored by Jiangsu HengRui Medicine Co., Ltd. · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
18
Allocation
Not applicable
Ages
18 Years to 45 Years
Sex
All
01

Study summary

The study is being conduct to evaluate fluconazole effect of on SHR2554 in condition of single-canter, open-label, single-dose in healthy subjects. To explore the SHR2554 pharmacokinetics change under use of fluconazole and insure the safety with SHR2554 combined with fluconazole.

02

Conditions studied

  • Malignant Tumor

Browse trials for

03

In context

Neoplasms

10,826 studies on the registry are indexed under Neoplasms; 2,322 are open to participants now.

This study's enrollment of 18 is below the median of 60 across 7,707 interventional studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

Jiangsu HengRui Medicine Co., Ltd. is the lead sponsor of 573 studies on the registry; 88 are open to participants now.

Of its 10 completed or terminated interventional studies of FDA-regulated products, 1 (10%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Sign the form before the trial, fully understand the trial process and possible adverse reactions in trail, and be able to complete the research in accordance with the requirements of the trail protocol;
  2. Healthy male and female subjects aged 18 to 45 year the date of signing the informed consent form, with female subjects ratio is not less than 40%;
  3. Male subjects weighed ≥ 50kg, female subjects weighed ≥ 45kg, and (BMI) was in the range of 19.0\~26.0kg/m2 (including the cut-off value);
  4. No family plan for the next 30 days and voluntary use of highly effective during the trial.

Exclusion criteria

Exclusion Criteria:

  1. Allergies, including severe drug allergies or drug allergies; history of allergy to SHR2554 tablets, fluconazole capsules, or their ;
  2. A clear history of primary diseases of important organs such as nervous system, cardiovascular system, urinary system, digestive system, respiratory system, metabolic and musculoskeletal system, including but not limited to tumour patients or tumour history, which the investigator believes is not suitable to participate in this study;
  3. During screening, comprehensive physical examination, vital signs examination (breathing, blood pressure, pulse and body temperature), chest orthostatic X-ray, and laboratory tests (blood biochemistry, blood routine, urine routine, immunization eight, coagulation function, female pregnancy) and other abnormal clinical significance (subject to the judgment of the clinician);
  4. Screening of male ≥ 430 msec or female QTcF ≥ 450 msec by examination, or abnormal clinical significance judged by the investigator in the ECG results;
  5. Have a history of drug and/or alcohol abuse, positive alcohol and drug screening, or have a history of drug abuse within the past five years or have used drugs in the 3 months before the trail;
  6. Addicts to tobacco and alcohol (drinking ≥ 14 units of alcohol per week) in the 3 months before screening: 1 unit = 360mL of beer, or 45mL of spirits, or 150mL of wine; Those who smoke ≥5 cigarettes) daily and cannot ban smoking and alcohol during the test;
  7. Those who have undergone any surgery within 6 months before screening;
  8. Hepatotoxic drugs (such as itraconazole, dapsone, erythromycin, fluconazole, ketoconazole, rifampicin, isoniazid, tetracycline, glibenclamide, propylthiouracil, methimazole, statin lipid-lowering drugs, fenofibrate, etc.) within 6 months before screening;
  9. Use of any drugs that alter the activity of enzyme (such as carbamazepine, phenytoin, modafinil, ritonavir, voriconazole, St. John's wort, bosentan tablets, efavirenz, etravirine, ciprofloxacin, etc.) within 28 days before taking the study drug;
  10. Use of any prescription drug, over-the-counter drug, vitamin product, supplement or herbal medicine within 14 days before taking the trail drug;
  11. ingested grapefruit or grapefruit-containing products, caffeinated, xanthine, or alcoholic foods or beverages within 48 hours prior to taking the study drug; strenuous exercise, or other factors that affect drug absorption, distribution, metabolism, excretion and other factors;
  12. Those who participated in blood donation within 3 months before taking the study drug and donated blood ≥ 200mL, or received blood transfusion;
  13. Those with a history of needle sickness and blood sickness, difficulty in blood collection or inability to tolerate venous puncture blood collection;
  14. female subjects lactating; Male subjects who have a sperm donation plan from the signing of the form until 30 days after the last dose of the experimental drug;
  15. Those who have participated in other drug trials within 3 months before screening;
  16. participants who the investigator believes have other factors that are not suitable for participation in this trial.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
18 participants (actual)

Study arms

  • Experimental
    Treatment group A

    SHR2554+ Fluconazole Capsules

    Drug: SHR2554 Tablets · Drug: Fluconazole Capsules

Interventions

06

What researchers measure

Primary outcomes

  1. Pharmacokinetic parameters of SHR2554: Cmax

    Time frame: day 1 to day 10

  2. Pharmacokinetic parameters of SHR2554: AUC0-t

    Time frame: day 1 to day 10

  3. Pharmacokinetic parameters of SHR2554: AUC0-∞

    Time frame: day 1 to day 10

Secondary outcomes

  1. Pharmacokinetic parameters of SHR2554: Tmax

    Time frame: day 1 to day 10

  2. Pharmacokinetic parameters of SHR2554: t1/2

    Time frame: day 1 to day 10

  3. Pharmacokinetic parameters of SHR2554: CL/F

    Time frame: day 1 to day 10

  4. Pharmacokinetic parameters of SHR2554: Vz/F

    Time frame: day 1 to day 10

  5. The incidence and severity of adverse events/serious adverse events

    Time frame: from ICF signing date to approximate day 18

07

Study locations

1 site
  • Beijing Tongren Hospital Affiliated to Capital Medical University
    Beijing, Beijing 100730, China
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2023 to primary completion in Mar 2023, 1 month.

Of 677 industry-sponsored phase 1 interventional studies under Neoplasms, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 62. This study's 1 month is below that.

Counting every sponsor, half of 904 studies reached it within 40 months; a quarter within 23 and three quarters within 64.

Neoplasms covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 15, 2022
First posted
Dec 22, 2022
StartActual
Feb 28, 2023
Primary completionActual
Mar 31, 2023
CompletionActual
Mar 31, 2023
Last update
Apr 4, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 4, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05661591
Responsible party
Sponsor
First posted
Dec 22, 2022
Start date
Feb 28, 2023
Primary completion
Mar 31, 2023
Completion
Mar 31, 2023
Last update
Apr 4, 2023

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Zeprumetostat

Start the discussion